HRD: What does it really mean and are we looking at this the right way?

Editor’s Choice: Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 studyEditorial: Testing for homologous recombination deficiency – does it provide new insights for the use of veliparib?Hosted by: Warner K. Huh, MD, FACOG, FACS, Deputy Editor of Gynecologic OncologyFeaturing:Elizabeth Swisher, MD, UW MedicineJonathan A Ledermann, MD FRCP FMedSci Professor of Medical Oncology, UCL Cancer InstituteCheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net